Romesh R. Subramanian
Direktor/Vorstandsmitglied bei Ceptur Therapeutics, Inc.
Profil
Romesh R.
Subramanian was the founder of Translate Bio, Inc. (founded in 2011) where he held the title of Senior Director from 2011 to 2014, and Dyne Therapeutics, Inc. (founded in 2017) where he held the title of Chief Scientific Officer from 2019 to 2021.
He is currently a Director at Ceptur Therapeutics, Inc. since 2022.
Dr. Subramanian's former positions include President & Chief Executive Officer at Ascidian Therapeutics, Inc. from 2022 to 2023, and Senior Director-Discovery Research at Alexion Pharmaceuticals, Inc. from 2014 to 2017.
Dr. Subramanian's education history includes a graduate degree from Duke University, a doctorate degree from Emory University (conferred in 2001), and an undergraduate degree from Loyola College (India).
Aktive Positionen von Romesh R. Subramanian
| Unternehmen | Position | Beginn |
|---|---|---|
Ceptur Therapeutics, Inc.
 Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Direktor/Vorstandsmitglied | 21.03.2022 |
Ehemalige bekannte Positionen von Romesh R. Subramanian
| Unternehmen | Position | Ende |
|---|---|---|
Ascidian Therapeutics, Inc.
 Ascidian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascidian Therapeutics, Inc. operates as a biotechnology research and development company. The company is headquartered in Brighton, MA. | Vorstandsvorsitzender | 08.11.2023 |
| DYNE THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.10.2019 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.10.2017 |
| TRANSLATE BIO, INC. | Gründer | 01.06.2014 |
Ausbildung von Romesh R. Subramanian
| Duke University | Graduate Degree |
| Emory University | Doctorate Degree |
| Loyola College (India) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| DYNE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Translate Bio, Inc.
 Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Ceptur Therapeutics, Inc.
Ceptur Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Ceptur Therapeutics, Inc. is a company that focuses on developing medicines for severe diseases in the areas of oncology, the central nervous system, nephrology, and immunology. The company is based in Hillsborough, NJ and has subsidiaries in the United States. The company is revolutionizing RNA therapeutics with U1 adaptor technology to address unaddressed diseases. The company was founded by Rafal Goraczniak and P. Peter Ghoroghchian, with P. Peter Ghoroghchian serving as CEO since incorporation. | Health Technology |
Ascidian Therapeutics, Inc.
Ascidian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascidian Therapeutics, Inc. operates as a biotechnology research and development company. The company is headquartered in Brighton, MA. | Health Technology |
